# Silent Heart Attack Market

> Silent Heart Attack Market Research Report Information By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications, Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End-User (Hospital, Clinic, Diagnostic Center) - Global Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.14%
- **2024:** $ 5.16 Billion
- **2025:** $ 5.53 Billion
- **2035:** $ 11.02 Billion
- **Key Players:** Pfizer Inc(US), Bristol-Myers Squibb Company (US), AstraZeneca PLC (GB), NovartisAG (CH), Merck & Co., Inc. (US), Johnson & Johnson (US), AbbVie Inc (US), Sanofi S.A. (FR), Gilead Sciences, Inc. (US)

**Report ID:** MRFR/Pharma/3563-HCR · **Pages:** 110 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/silent-heart-attack-market-4998

---

## Market Summary

## **Silent Heart Attack Market Overview**

Silent Heart Attack Market Size was valued at USD 4.53 Billion in 2023. The Global Silent Heart Attack industry is projected to grow from USD 5.16 Billion in 2024 to USD 12.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.14% during the forecast period (2024 - 2032). 

**In August 2023,** the Indian Council of Medical Research (ICMR) has just begun two major studies to investigate the mystery behind the unusually high number of young people dying suddenly after the COVID-19 pandemic. Dr Rajiv Bahl, Director-General of ICMR, told News18 about these audacious projects on the sidelines of the WHO Global Traditional Medicine Summit that was held in Gujarat on August 17 and 18.

**PocDoc recently announced in June 2024** that its home test kit for cardiovascular disease (CVD) will include a new feature allowing patients to view test results on their NHS patient records. The PocDoc at-home kit establishes point-of-care diagnostic testing for CVD with a complete cholesterol panel, and data such as heart age, 10-year risk of heart attack or stroke, and BMI are found within the PocDoc app. Patients also get access to further treatment options if required.

**In April 2024,** Huntington Medical Research Institutes and California Institute of Technology (Caltech), located in Pasadena, witnessed a groundbreaking cardiovascular medicine development when an outstanding, innovative young researcher made significant progress toward developing a noninvasive method for diagnosing heart attacks and heart failure. At present, cardiovascular researchers at the Institutes have made headway in artificial intelligence applications for detecting silent and super-silent heart attacks.

The Indian Bollywood actress, Sushmita Sen, suffered a heart attack on Thursday but she is now doing fine. This information was shared by ‘Sush’ through social media after work last Thursday. To the surprise of many, fitness enthusiast Sushmita Sen had undergone angioplasty after experiencing a sudden cardiac arrest. It is used to reinstate blood flow via narrowed or blocked vessels as performed by medical professionals. In the operation they put in an inflatable balloon at the end of a catheter that goes into this artery.

By doing so, it lets more of that fluid flow much easier and prevents clogs from causing heart attacks or strokes later in life. The procedure can be done with or without using a stent which is like a small metallic mesh tube placed inside your arteries to keep them open for you.

Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.

According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.

The Silent Heart Attack Market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.

## **Silent Heart Attack Market Segmentation**

Silent Heart Attack Market is segmented on the basis of Diagnosis, Indication, Devices, and End User.

On the basis of diagnosis, market is segmented into cardiac computerized [tomography](../../../reports/positron-emission-tomography-devices-market-7254), [magnetic resonance imaging](../../../reports/magnetic-resonance-imaging-systems-market-6194), electrocardiogram, echocardiogram, blood tests, and others.

On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, [coronary artery bypass](../../../reports/coronary-artery-bypass-graft-market-2285) surgery, and others.

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.

## **Regional Analysis of the Silent Heart Attack Market**

America accounts for the largest market for the silent heart attack. The increasing prevalence of cardiovascular diseases and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.

Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the Silent Heart Attack Market.

Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.

In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by the presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.

## **Key Players in the Silent Heart Attack Market**

Some of the key players in Silent Heart Attack Market are: 

- [Siemens (U.S.)](https://www.siemens-healthineers.com/en-us/press-room/press-releases/heart-attacks-data-press-release)
- Schiller AG
- Midmark Corporation
- Koninklijke Philips N.V. (Japan) 
- Bionet (Korea)
- Welch Allyn (U.S.)
- Toshiba Medical Systems Corporation (Japan)
- AstraZeneca plc (U.K)
- Pfizer (U.S.)
- Sanofi (France)
- Merck & Co. (U.S.)
- Daiichi Sankyo Company Limited
- Novartis AG (Germany)
- Bayer (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Boehringer Ingelheim GmbH (Germany)
- Astellas Pharma Inc. (Japan)
- Johnson & Johnson (U.S.)
- United Therapeutics Corporation (U.S.)
- Actelion Pharmaceuticals Ltd. (Switzerland) 
- F. Hoffmann-La Roche Ltd (Switzerland)

**Intended Audience**

- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

## Market Drivers

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic tools are transforming the Silent Heart Attack Market. The development of advanced imaging techniques, such as cardiac MRI and CT angiography, allows for more accurate detection of silent heart attacks. These technologies enable healthcare professionals to identify underlying cardiovascular issues before they escalate into critical conditions. Furthermore, wearable devices equipped with heart monitoring capabilities are gaining traction, providing real-time data to both patients and physicians. As these technologies become more accessible and affordable, the market is expected to expand significantly. The integration of artificial intelligence in diagnostic processes may also enhance the accuracy and efficiency of identifying silent heart attacks, further driving market growth.

### Increased Public Awareness and Education

Public awareness and education regarding silent heart attacks are crucial drivers for the Silent Heart Attack Market. As more individuals become informed about the risks and symptoms associated with silent heart attacks, there is a growing demand for screening and diagnostic services. Educational initiatives by healthcare organizations aim to highlight the importance of recognizing risk factors and the need for regular check-ups. This heightened awareness is likely to lead to increased patient engagement in their health management, resulting in more individuals seeking preventive care. Consequently, healthcare providers may respond by expanding their offerings related to silent heart attack detection and management, thereby fostering growth within the Silent Heart Attack Market.

### Rising Incidence of Silent Heart Attacks

The increasing prevalence of silent heart attacks is a critical driver for the Silent Heart Attack Market. Research indicates that approximately 45% of heart attacks are silent, often going undiagnosed until more severe complications arise. This trend is particularly concerning among older adults and individuals with diabetes, who are at a higher risk. As awareness grows regarding the asymptomatic nature of these events, healthcare providers are likely to enhance screening protocols. Consequently, this may lead to a surge in demand for diagnostic tools and monitoring devices tailored for early detection. The Silent Heart Attack Market is thus poised for growth as healthcare systems adapt to address this silent epidemic.

### Growing Emphasis on Preventive Healthcare

The shift towards preventive healthcare is a notable driver for the Silent Heart Attack Market. As healthcare systems increasingly prioritize prevention over treatment, there is a heightened focus on early detection of cardiovascular diseases. This trend is reflected in the rising adoption of routine screenings and health assessments aimed at identifying risk factors associated with silent heart attacks. Public health campaigns promoting heart health awareness are also contributing to this shift. Consequently, healthcare providers are likely to invest in resources and technologies that facilitate early diagnosis, thereby expanding the Silent Heart Attack Market. The potential for reducing healthcare costs associated with late-stage interventions further underscores the importance of this preventive approach.

### Aging Population and Increased Risk Factors

The aging population presents a significant driver for the Silent Heart Attack Market. As individuals age, the risk of cardiovascular diseases, including silent heart attacks, escalates. Factors such as hypertension, high cholesterol, and diabetes are prevalent among older adults, contributing to the likelihood of undetected heart issues. This demographic shift necessitates enhanced healthcare services focused on monitoring and managing heart health. Additionally, the increasing life expectancy means that more individuals are living with chronic conditions that may predispose them to silent heart attacks. As a result, the demand for diagnostic tools and preventive measures within the Silent Heart Attack Market is expected to rise, prompting healthcare systems to adapt accordingly.

## Future Outlook

The Silent Heart Attack Market is projected to grow at a 7.14% CAGR from 2025 to 2035, driven by increasing awareness, technological advancements, and rising healthcare expenditures.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection. Expansion of telehealth services for remote patient monitoring. Partnerships with fitness apps for heart health tracking and education.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced awareness and innovative solutions.

## Segment Insights

### By Diagnosis: Electrocardiogram (Largest) vs. Magnetic Resonance Imaging (Fastest-Growing)

The Silent Heart Attack Market has witnessed notable distribution across various diagnostic tools, with electrocardiogram (ECG) emerging as the dominant player due to its widespread use in detecting silent myocardial ischemia. Following ECG, cardiac computerized tomography and echocardiograms hold substantial shares, providing complementary insights that aid in early detection. Blood tests also contribute significantly, while magnetic resonance imaging is carving out a notable role, particularly in niche applications. Growth trends in this market are driven by an increasing awareness of silent heart attacks and advancements in diagnostic technologies. Electrocardiograms remain prevalent due to their accessibility and cost-effectiveness. However, magnetic resonance imaging is positioning itself as an innovative tool with rapid growth attributed to improved imaging capabilities and non-invasive nature. This trend highlights a broader shift towards comprehensive diagnostics and personalized healthcare solutions for cardiovascular diseases.

Electrocardiogram (Dominant) vs. Magnetic Resonance Imaging (Emerging)

Electrocardiograms (ECGs) serve as the backbone of diagnostic methods in the Silent Heart Attack Market due to their ability to provide quick and reliable heart activity assessment. This method is widely adopted in clinical settings owing to its low cost and ease of use, enabling routine screenings and continuous monitoring. In contrast, magnetic resonance imaging (MRI) is becoming an emerging player, offering high-resolution imaging and detailed cardiac assessments that can detect subtle changes undetectable by traditional methods. This advanced technology benefits from innovations that enhance patient comfort and reduce scan times, positioning MRI as a vital tool for early diagnosis and risk stratification in patients at risk of silent heart attacks.

### By Indication: Medications (Largest) vs. Coronary Angioplasty and Stenting (Fastest-Growing)

In the Silent Heart Attack Market, the market share is predominantly led by the medications segment, which accounts for a significant portion of the overall market due to their role in managing symptoms and preventing further cardiac events. This segment benefits from broad adoption in clinical settings, emphasizing preventative care and symptom management, making it essential for patient outcomes. Following closely is the coronary angioplasty and stenting segment, which has gained traction as more patients are diagnosed and treated for silent heart attacks, as well as the increased focus on minimally invasive procedures.

Medications (Dominant) vs. Coronary Angioplasty and Stenting (Emerging)

The medications segment is characterized by a diverse range of pharmaceutical options aimed at different aspects of heart health, including blood thinners, beta-blockers, and ACE inhibitors. This wide variety enables healthcare providers to customize treatment plans, enhancing patient outcomes. However, the coronary angioplasty and stenting segment is emerging rapidly due to technological advancements, enabling safer and more effective interventions with shorter recovery times. This method is becoming increasingly favorable among clinicians as they seek to improve the quality of care for silent heart attack patients, thus driving growth in this segment.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Silent Heart Attack Market, hospitals hold the largest market share among the end user segments, primarily due to their advanced diagnostic and treatment facilities. Clinics and diagnostic centers follow, with a significant yet smaller share, catering to less severe cases or providing preliminary diagnoses. The distribution of market share reflects the traditional reliance on hospitals for comprehensive care, while newer facilities like clinics are gaining traction.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals stand as the dominant end user in the Silent Heart Attack Market, equipped with extensive resources and specialized staff to manage complex cases. These institutions not only provide emergency services but also leverage advanced technology for diagnosis and treatment. On the other hand, clinics are emerging rapidly, driven by the increasing demand for accessible healthcare services and preventive measures. They play a crucial role in early detection and management of silent heart attacks, appealing to patients seeking convenience and quicker service, thus reshaping the market landscape.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America is the largest market for silent heart attacks, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high awareness levels, and significant investments in research and development. Regulatory support from agencies like the FDA further drives innovation and adoption of new therapies, enhancing patient outcomes and treatment options. The growing prevalence of cardiovascular diseases is also a key demand driver, pushing for more effective management solutions. The United States is the leading country in this market, followed by Canada, which contributes significantly to the overall growth. Major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson are heavily invested in developing treatments for silent heart attacks. The competitive landscape is characterized by a focus on innovative therapies and partnerships, ensuring a robust pipeline of products aimed at improving patient care and outcomes.

### Europe : Emerging Regulatory Frameworks

Europe is witnessing a growing focus on silent heart attack management, holding around 30% of the global market share. The region's growth is driven by increasing awareness of cardiovascular health, supportive regulatory frameworks, and collaborative initiatives among healthcare providers. Countries like Germany and France are at the forefront, implementing policies that encourage early detection and intervention, which are crucial for improving patient outcomes. The European Medicines Agency (EMA) plays a vital role in facilitating the approval of innovative therapies, further enhancing market dynamics. Germany, France, and the UK are leading countries in this market, with a strong presence of key players such as AstraZeneca and Novartis. The competitive landscape is marked by strategic partnerships and a focus on research and development to address unmet medical needs. The emphasis on preventive healthcare and patient education is also shaping the market, ensuring that silent heart attacks are recognized and treated effectively.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is emerging as a significant player in the silent heart attack market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of cardiovascular diseases, and a growing aging population. Countries like China and India are witnessing a surge in demand for effective treatment options, supported by government initiatives aimed at improving healthcare access and quality. Regulatory bodies are also becoming more proactive in approving new therapies, which is essential for market expansion. China and Japan are the leading countries in this market, with a competitive landscape that includes both local and international players. Companies like Gilead Sciences and AbbVie are actively involved in developing innovative solutions for silent heart attacks. The market is characterized by a mix of established pharmaceutical firms and emerging biotech companies, all striving to meet the increasing demand for effective cardiovascular treatments.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually recognizing the importance of addressing silent heart attacks, holding about 5% of the global market share. The growth in this region is driven by increasing awareness of cardiovascular health, rising healthcare investments, and the need for improved healthcare infrastructure. Countries like South Africa and the UAE are leading efforts to enhance cardiovascular care, supported by government initiatives aimed at improving health outcomes. Regulatory bodies are beginning to focus on establishing guidelines for the management of silent heart attacks, which is crucial for market development. South Africa and the UAE are the primary markets in this region, with a competitive landscape that includes both local and international pharmaceutical companies. The presence of key players is growing, with companies like Sanofi and Merck expanding their portfolios to include treatments for silent heart attacks. The market is characterized by a focus on education and awareness campaigns to promote early detection and management of cardiovascular diseases.

## Competitive Benchmarking

The Silent Heart Attack Market is characterized by a complex interplay of competitive dynamics, driven by an increasing awareness of cardiovascular health and the silent nature of these events. Key players such as Pfizer Inc (US), AstraZeneca PLC (GB), and Johnson & Johnson (US) are strategically positioned to leverage their extensive research capabilities and established market presence. Pfizer Inc (US) focuses on innovative therapeutic solutions, while AstraZeneca PLC (GB) emphasizes partnerships to enhance its research pipeline. Johnson & Johnson (US) is actively pursuing digital health initiatives, which collectively shape a competitive environment that is increasingly reliant on innovation and strategic collaborations.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Silent Heart Attack Market appears moderately fragmented, with a mix of established pharmaceutical giants and emerging players. The collective influence of these key players fosters a competitive structure that encourages innovation and rapid adaptation to changing healthcare landscapes.

In August 2025, Pfizer Inc (US) announced a collaboration with a leading digital health company to develop a mobile application aimed at early detection of silent heart attacks. This strategic move underscores Pfizer's commitment to integrating technology into healthcare solutions, potentially enhancing patient engagement and monitoring. Such initiatives may not only improve patient outcomes but also position Pfizer as a leader in the digital health space.

In September 2025, AstraZeneca PLC (GB) launched a new clinical trial focusing on a novel biomarker for silent heart attacks. This initiative reflects AstraZeneca's dedication to advancing research in cardiovascular health and could lead to breakthroughs in early detection and treatment. The emphasis on biomarker research may provide AstraZeneca with a competitive edge in a market that increasingly values precision medicine.

In July 2025, Johnson & Johnson (US) expanded its cardiovascular portfolio by acquiring a startup specializing in AI-driven diagnostic tools for heart conditions. This acquisition highlights Johnson & Johnson's strategy to enhance its technological capabilities and integrate artificial intelligence into its product offerings. The move is likely to strengthen its market position by providing innovative solutions that address unmet needs in silent heart attack detection.

As of October 2025, current competitive trends in the Silent Heart Attack Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming pivotal in shaping the landscape, as companies seek to combine resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may redefine how companies engage with healthcare providers and patients, ultimately enhancing the overall quality of care.

## Report Scope

| MARKET SIZE 2024 | 5.16(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.528(USD Billion) |
| MARKET SIZE 2035 | 11.02(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.14% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer Inc (US), Bristol-Myers Squibb Company (US), AstraZeneca PLC (GB), Novartis AG (CH), Merck & Co., Inc. (US), Johnson & Johnson (US), AbbVie Inc (US), Sanofi S.A. (FR), Gilead Sciences, Inc. (US) |
| Segments Covered | Diagnosis |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection in the Silent Heart Attack Market. |
| Key Market Dynamics | Rising awareness of silent heart attacks drives demand for advanced diagnostic technologies and preventive healthcare solutions. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Silent Heart Attack Market in 2035?**
A: The projected market valuation for the Silent Heart Attack Market in 2035 is 11.02 USD Billion.

**Q: What was the market valuation of the Silent Heart Attack Market in 2024?**
A: The overall market valuation of the Silent Heart Attack Market was 5.16 USD Billion in 2024.

**Q: What is the expected CAGR for the Silent Heart Attack Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Silent Heart Attack Market during the forecast period 2025 - 2035 is 7.14%.

**Q: Which segment is projected to have the highest valuation in the Diagnosis category?**
A: In the Diagnosis category, the electrocardiogram segment is projected to have the highest valuation, increasing from 1.2 to 2.5 USD Billion.

**Q: What are the key players in the Silent Heart Attack Market?**
A: Key players in the Silent Heart Attack Market include Pfizer Inc, Bristol-Myers Squibb Company, AstraZeneca PLC, and others.

**Q: Which end user segment is expected to grow significantly by 2035?**
A: The hospitals segment is expected to grow significantly, with a projected increase from 1.55 to 3.25 USD Billion.

**Q: What is the projected growth for blood tests in the Diagnosis segment?**
A: The blood tests segment in the Diagnosis category is projected to grow from 0.6 to 1.2 USD Billion.

**Q: How does the coronary angioplasty and stenting segment perform in the Indication category?**
A: The coronary angioplasty and stenting segment in the Indication category is projected to grow from 1.2 to 2.5 USD Billion.

**Q: What is the expected growth for diagnostic centers as an end user?**
A: The diagnostic centers segment is expected to grow from 1.1 to 2.3 USD Billion by 2035.

**Q: What does the market data suggest about the Silent Heart Attack Market's future?**
A: The market data suggests that the Silent Heart Attack Market is likely to experience robust growth, driven by advancements in diagnosis and treatment.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/silent-heart-attack-market-4998*